Clarivate (NYSE:CLVT) Trading 7% Higher – Still a Buy?

Posted by Brian Himes on Jul 2nd, 2026

Shares of Clarivate PLC (NYSE:CLVT – Get Free Report) shot up 7% on Thursday . The company traded as high as $2.41 and last traded at $2.3750. 1,363,752 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 6,657,492 shares. The stock had previously closed at $2.22.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CLVT. Citigroup cut their price target on shares of Clarivate from $4.25 to $2.80 and set a “neutral” rating on the stock in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Five equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Clarivate has an average rating of “Reduce” and a consensus target price of $3.22.

Read Our Latest Report on CLVT

Clarivate Price Performance

The firm has a fifty day moving average of $2.42 and a two-hundred day moving average of $2.59. The stock has a market capitalization of $1.58 billion, a P/E ratio of -11.79 and a beta of 1.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.84 and a quick ratio of 0.84.

Clarivate (NYSE:CLVT – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The business had revenue of $585.50 million for the quarter, compared to the consensus estimate of $569.50 million. During the same quarter last year, the firm posted $0.14 EPS. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, analysts predict that Clarivate PLC will post 0.65 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. American Century Companies Inc. raised its holdings in Clarivate by 20.6% in the third quarter. American Century Companies Inc. now owns 9,973,797 shares of the company’s stock worth $38,200,000 after purchasing an additional 1,706,306 shares in the last quarter. Iridian Asset Management LLC CT boosted its holdings in shares of Clarivate by 52.4% in the 4th quarter. Iridian Asset Management LLC CT now owns 1,528,410 shares of the company’s stock valued at $5,105,000 after buying an additional 525,452 shares in the last quarter. Cove Street Capital LLC grew its position in shares of Clarivate by 4,075.2% in the 3rd quarter. Cove Street Capital LLC now owns 452,462 shares of the company’s stock worth $1,733,000 after buying an additional 441,625 shares during the last quarter. BW Gestao de Investimentos Ltda. raised its stake in shares of Clarivate by 51.7% during the 4th quarter. BW Gestao de Investimentos Ltda. now owns 4,345,321 shares of the company’s stock worth $14,513,000 after acquiring an additional 1,480,300 shares in the last quarter. Finally, LSV Asset Management lifted its position in Clarivate by 25.6% during the fourth quarter. LSV Asset Management now owns 2,647,900 shares of the company’s stock valued at $8,844,000 after acquiring an additional 540,400 shares during the last quarter. 85.72% of the stock is owned by institutional investors.

About Clarivate

(Get Free Report)

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.